Dodekin is a fully-human immunostimulatory product consisting of a vascular targeting antibody fused to interleukin-12 (IL12), generating a tumor-targeted product that selectively localize at the site of disease, while sparing healthy organs.
Dodekin has shown potent anti-tumor activity both as single agent and in combination with checkpoint inhibitors in several immunocompetent preclinical models, in which long-lasting complete responses have been observed.
Dodekin has also shown striking single-agent anti-cancer activity in orthotopic mouse models of glioblastoma (studies performed in collaboration with the University Hospital Zurich). The treatment induced long-term tumor eradications in a substantial proportion of treated animals, which could not be cured with standard therapies.
Based on the encouraging preclinical results, Philogen has started a phase I/II (TBD if I or I/II) clinical trial in patients with advanced solid tumors that have progressed after immune-checkpoint therapy. Dodekin is a partnered program.
ONGOING CLINICAL TRIALS
- A phase I study to evaluate safety and early signs of efficacy of Dodekin in patients with advanced solid carcinomas and DLBCL after previous immune-checkpoint blockade therapy (NCT04471987).
ONGOING CLINICAL TRIALS
- A phase I study to evaluate safety and early signs of efficacy of Dodekin in patients with advanced solid carcinomas and DLBCL after previous immune-checkpoint blockade therapy (NCT04471987).
References
Weiss et al., (2020) Sci Transl Med, 12 (564):eabb2311
Puca et al. (2020) Int J Cancer, 146, 2518-30
Hutmacher et al. (2019) Cancer Immune Res, 7, 572-83
Ongaro et al. (2019) J Biotechnol, 291, 17-25
Mosely et al. (2017) Cancer Immunol Res, 5, 29-41
Hemmerle & Neri (2014) Int J Cancer, 134, 467-77
Lasek et al. (2014) Cancer Immunol Immunother, 63, 419-35
Pasche et al. (2012) Clin Cancer Res, 12, 4092-103
Sommavilla et al. (2010) Protein Engin Des Sel, 23, 653-61
Gafner et al. (2006) Int J Cancer, 119, 2205-12
Halin et al. (2003) Cancer Res, 63, 3202-10
Halin et al. (2002) Nat Biotechnol, 20, 264-9
Castellani et al. (2002) Am . Pathol, 161, 1695-1700